WallStSmart

CryoCell International Inc (CCEL)vsEncompass Health Corp (EHC)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

Encompass Health Corp generates 20262% more annual revenue ($6.34B vs $31.13M). EHC leads profitability with a 10.2% profit margin vs -6.3%. EHC appears more attractively valued with a PEG of 0.41. EHC earns a higher WallStSmart Score of 68/100 (B-).

CCEL

Hold

47

out of 100

Grade: D+

Growth: 6.0Profit: 5.0Value: 7.0Quality: 5.5
Piotroski: 6/9Altman Z: -0.53

EHC

Strong Buy

68

out of 100

Grade: B-

Growth: 7.3Profit: 7.5Value: 6.0Quality: 6.0
Piotroski: 6/9Altman Z: 2.12
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

CCELUndervalued (+33.5%)

Margin of Safety

+33.5%

Fair Value

$5.02

Current Price

$4.15

$0.87 discount

UndervaluedFair: $5.02Overvalued
EHCSignificantly Overvalued (-47.1%)

Margin of Safety

-47.1%

Fair Value

$77.11

Current Price

$133.65

$56.54 premium

UndervaluedFair: $77.11Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CCEL3 strengths · Avg: 10.0/10
Return on EquityProfitability
129.2%10/10

Every $100 of equity generates 129 in profit

EPS GrowthGrowth
75.1%10/10

Earnings expanding 75.1% YoY

Debt/EquityHealth
-0.0410/10

Conservative balance sheet, low leverage

EHC3 strengths · Avg: 9.0/10
PEG RatioValuation
0.4110/10

Growing faster than its price suggests

Return on EquityProfitability
24.0%9/10

Every $100 of equity generates 24 in profit

EPS GrowthGrowth
21.6%8/10

Earnings expanding 21.6% YoY

Areas to Watch

CCEL4 concerns · Avg: 3.0/10
Revenue GrowthGrowth
0.0%4/10

0.0% revenue growth

Market CapQuality
$39.10M3/10

Smaller company, higher risk/reward

Operating MarginProfitability
0.6%3/10

Operating margin of 0.6%

Altman Z-ScoreHealth
-0.532/10

Distress zone — elevated risk

EHC1 concerns · Avg: 3.0/10
Debt/EquityHealth
1.053/10

Elevated debt levels

Comparative Analysis Report

WallStSmart Research

Bull Case : CCEL

The strongest argument for CCEL centers on Return on Equity, EPS Growth, Debt/Equity. PEG of 1.34 suggests the stock is reasonably priced for its growth.

Bull Case : EHC

The strongest argument for EHC centers on PEG Ratio, Return on Equity, EPS Growth. PEG of 0.41 suggests the stock is reasonably priced for its growth.

Bear Case : CCEL

The primary concerns for CCEL are Revenue Growth, Market Cap, Operating Margin.

Bear Case : EHC

The primary concerns for EHC are Debt/Equity.

Key Dynamics to Monitor

CCEL profiles as a turnaround stock while EHC is a value play — different risk/reward profiles.

EHC carries more volatility with a beta of 0.67 — expect wider price swings.

EHC is growing revenue faster at 8.9% — sustainability is the question.

EHC generates stronger free cash flow (128M), providing more financial flexibility.

Bottom Line

EHC scores higher overall (68/100 vs 47/100). CCEL offers better value entry with a 33.5% margin of safety. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

CryoCell International Inc

HEALTHCARE · MEDICAL CARE FACILITIES · USA

Cryo-Cell International, Inc. is dedicated to cell processing and cryogenic cell storage with a focus on collecting and preserving umbilical cord blood stem cells for family use. The company is headquartered in Oldsmar, Florida.

Encompass Health Corp

HEALTHCARE · MEDICAL CARE FACILITIES · USA

Encompass Health Corporation offers in-home and post-acute health care services in the United States. The company is headquartered in Birmingham, Alabama.

Want to dig deeper into these stocks?